Travoprost-loaded punctum plug: Phase II data

Top-line data from an open-label South African Phase II trial in 36 eyes from 20 patients with open-angle glaucoma or ocular hypertension showed that OTX-TP2 led to a reduction in mean IOP of 6.8 mmHg from baseline to day 60. Additionally, OTX-TP2 reduced mean IOP by 7.2 mmHg from baseline to day 15, by 6.6 mmHg at day 30 and by 6.7 mmHg at day 45. Mean IOP at baseline was 28.7 mmHg. Ocular Therapeutix said the results were comparable to that observed with the marketed topical ophthalmic solutions Travatan Z travoprost, Lumigan bimatoprost and Xalatan latanoprost. No excessive tearing or other unanticipated adverse events were reported. The company did not conduct statistical testing for the reductions in IOP. ...